Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed loco-regionally advanced non-small cell lung cancer meeting one of the following staging criteria: Medically inoperable stage IIIA Unresectable stage IIIA or IIIB Measurable disease on three-dimensional planning CT scan No post-resection intrathoracic tumor recurrence No pleural effusion on chest x-ray except those occurring after attempted thoracotomy or other invasive thoracic procedure No evidence of small cell histology No evidence of hematogenous or distant metastases PATIENT CHARACTERISTICS: Age: Not specified Performance status: Zubrod 0-1 Life expectancy: Not specified Hematopoietic: Platelet count at least 100,000/mm^3 Absolute granulocyte count at least 2,000/mm^3 Hemoglobin at least 8.0 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL Serum glutamate oxaloacetate transaminase (SGOT) no greater than 1.5 times upper limit of normal (unless caused by documented benign disease) Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No myocardial infarction within the past 6 months No symptomatic heart disease, including angina, congestive heart failure, or uncontrolled arrhythmia Pulmonary: Forced expiratory volume (FEV)_1 greater than 1,000 mL Other: No other invasive malignancy within the past 3 years except nonmelanoma skin cancer No weight loss of more than 10% in 3 months prior to diagnosis Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior thoracic or neck radiotherapy Surgery: See Disease Characteristics No prior complete or subtotal tumor resection
Sites / Locations
- CCOP - Bay Area Tumor Institute
- University of Miami Sylvester Comprehensive Cancer Center
- Wendt Regional Cancer Center of Finley Hospital
- Monmouth Medical Center
- Akron City Hospital
- Cancer Care Center, Incorporated
- Delaware County Memorial Hospital
- Dale and Frances Hughes Cancer Center
- Mercy Hospital of Pittsburgh
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
- Cottonwood Hospital Medical Center
- McKay-Dee Hospital Center
- Utah Valley Regional Medical Center - Provo
- Dixie Regional Medical Center
- LDS Hospital
- Danville Regional Medical Center
- Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
- Medical College of Wisconsin Cancer Center
- Veterans Affairs Medical Center - Milwaukee (Zablocki)
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Arm 1
Arm 2
Arm 3
Arm 4
Arm 6
Arm 8
Arm 10
Arm 12
Arm 14
Arm 5
Arm 7
Arm 9
Arm 11
Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT